No Data
Earnings Preview: HALO to Report Financial Results Post-market on May 06
Alnylam, Halozyme Among Latest Firms to Win EU Backing for Drugs
Halozyme Therapeutics Says VYVGART to Treat Rare Autoimmune Disease Receives CHMP Recommendation
Halozyme to Report First Quarter 2025 Financial and Operating Results
Express News | Halozyme Announces argenx Received Positive Chmp Opinion for Vyvgart® (Efgartigimod Alfa) Subcutaneous Injection With Enhanze® for Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $72